Early Alzheimer's Disease

Neurology
7
Pipeline Programs
4
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
4
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 6 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Alzheon
AlzheonMA - Framingham
3 programs
1
2
Experimental: ALZ-801Phase 31 trial
Experimental: ALZ-801Phase 31 trial
ALZ-801Phase 21 trial
Active Trials
NCT04693520CompletedEst. Jul 2025
NCT06304883Active Not RecruitingEst. Jan 2027
NCT04770220CompletedEst. Jul 2024
E
EisaiChina - Liaoning
2 programs
1
1
Lecanemab IVPhase 31 trial
E2609Phase 11 trial
Active Trials
NCT02859207Completed32Est. Jan 2017
NCT03887455Active Not Recruiting1,906Est. Jun 2029
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
SemagludtidePhase 3Peptide1 trial
Active Trials
NCT04777396Active Not Recruiting1,840Est. Jan 2026
NewAmsterdam Pharma
NewAmsterdam PharmaNARRDEN, Netherlands
1 program
1
ObicetrapibPhase 21 trial
Active Trials
NCT05161715CompletedEst. Jun 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AlzheonExperimental: ALZ-801
AlzheonExperimental: ALZ-801
Novo NordiskSemagludtide
EisaiLecanemab IV
NewAmsterdam PharmaObicetrapib
AlzheonALZ-801
EisaiE2609

Clinical Trials (7)

Total enrollment: 3,778 patients across 7 trials

NCT06304883AlzheonExperimental: ALZ-801

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Start: Apr 2024Est. completion: Jan 2027
Phase 3Active Not Recruiting
NCT04770220AlzheonExperimental: ALZ-801

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

Start: May 2021Est. completion: Jul 2024
Phase 3Completed
NCT04777396Novo NordiskSemagludtide

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Start: May 2021Est. completion: Jan 20261,840 patients
Phase 3Active Not Recruiting
NCT03887455EisaiLecanemab IV

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Start: Mar 2019Est. completion: Jun 20291,906 patients
Phase 3Active Not Recruiting
NCT05161715NewAmsterdam PharmaObicetrapib

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

Start: Jan 2022Est. completion: Jun 2023
Phase 2Completed
NCT04693520AlzheonALZ-801

Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease

Start: Sep 2020Est. completion: Jul 2025
Phase 2Completed
NCT02859207EisaiE2609

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Start: Aug 2016Est. completion: Jan 201732 patients
Phase 1Completed

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
8h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
9h ago

Director of Finance

CoMind
London, UK
9h ago

Electronics Engineering Manager

CoMind
London, UK
9h ago

Director of Information Technology

Zavation Medical Products
9h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)